Overall, 75 patients with advanced nonsquamous NSCLC without EGFR mutation or ALK/ROS1 fusion have started treatment according to the KN-189 regimen between April 2018 and May 2021 at the University Hospital Basel. The gene discussed is ALK; the disease is non-small cell lung carcinoma.